AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: Updated results from the phase 1 non-enhancing glioma population Meeting Abstract

   

Authors:	Mellinghoff, I. K.; Touat, M.; Maher, E.; De La Fuente, M.; Cloughesy, T. F.; Holdhoff, M.; Cote, G. M.; Burris, H.; Janku, F.; Huang, R.; Young, R. J.; Ellingson, B.; Nimkar, T.; Jiang, L.; Ishii, Y.; Choe, S.; Fan, B.; Steelman, L.; Yen, K.; Bowden, C.; Pandya, S.; Wen, P. Y.
Abstract Title:	AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: Updated results from the phase 1 non-enhancing glioma population
Meeting Title:	22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
Journal Title:	Neuro-Oncology
Volume:	19
Issue:	Suppl. 6
Meeting Dates:	2017 Nov 16-19
Meeting Location:	San Francisco, CA
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2017-11-01
Start Page:	vi10
End Page:	vi11
Language:	English
ACCESSION:	WOS:000415152500038
PROVIDER:	wos
DOI:	10.1093/neuonc/nox168.037
PMCID:	PMC5691984
Notes:	Meeting Abstract: ACTR-46 -- Joint Conference of 22nd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology / Conference of the Society-for-CNS-Interstitial-Delivery-of-the-Therapeutics (SCIDOT) on Therapeutic Delivery to the CNS -- NOV 15-19, 2017 -- San Francisco, CA -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/120281